[go: up one dir, main page]

PE20030660A1 - Composiciones farmaceuticas y procedimientos para administrar agonistas selectivos del receptor ep2 - Google Patents

Composiciones farmaceuticas y procedimientos para administrar agonistas selectivos del receptor ep2

Info

Publication number
PE20030660A1
PE20030660A1 PE2002001133A PE2002001133A PE20030660A1 PE 20030660 A1 PE20030660 A1 PE 20030660A1 PE 2002001133 A PE2002001133 A PE 2002001133A PE 2002001133 A PE2002001133 A PE 2002001133A PE 20030660 A1 PE20030660 A1 PE 20030660A1
Authority
PE
Peru
Prior art keywords
rent
ring
sulfonil
alkylene
members
Prior art date
Application number
PE2002001133A
Other languages
English (en)
Inventor
Yesook Kim
Mei Li
Francis Dumont
Richard Wilker Korsmeyer
Jinyang Hong
Vishwas Madhav Paralkar
David Duane Thompson
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PE20030660A1 publication Critical patent/PE20030660A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE REFIERE A UNA COMPOSICION DE MICROPARTICULAS DE LIBERACION CONTROLADA PARA LA LIBERACION SOSTENIDA DE UN AGONISTA SELECTIVO DEL RECEPTOR PROSTAGLANDINAS EP2 DE FORMULA i)A-B(K-M)(Q-Z); B ES N, A ES ALQUIL-SULFONILO, CICLOALQUIL-SULFONILO, ENTRE OTROS; Q ES ALQUILEN-W-ALQUILEN, ALQUILEN-X-ALQUILEN, ENTRE OTROS; W ES OXI, TIO, SULFINO, SULFONILO, CARBOXAMIDO, CARBAMOILO, ENTRE OTROS; X ES UN ANILLO AROMATICO; Z ES CARBOXILO, TETRAZOLILO, ALCOXI-CARBONILO, ALQUIL-SULFONILCARBAMOILO, ENTRE OTROS; K ES UN ENLACE, ALQUILENO, TIOALQUILENO, OXIALQUILENO; M ES Ar, Ar1-V-Ar2, Ar1-S-Ar2, Ar1-O-Ar2; Ar, Ar1, Ar2 SON UN ANILLO DE 5-8 MIEMBROS, ANILLO BICICLICO; V ES UN ENLACE, ALQUILENO; ii)G-A-B-(K-M)(Q-Z) A ES SO2, CO, G ES Ar, Ar1-V-Ar2, Ar-ALQUILENO, R1R2-AMINO, OXIALQUILENO, AMINO; B ES N, CH, Q ES ALQUILEN, X-ALQUILEN, ALQUILEN-W-X-ALQUILEN, ENTRE OTROS; Z ES CARBOXILO, ALCOXICARBOXILO, TETRAZOLILO, ENTRE OTROS; K ES ENLACE, ALQUILENO, TIOALQUILENO, ENTRE OTROS; M ES Ar3, Ar4-V1-Ar5, Ar4-S-Ar5, ENTRE OTROS; Ar3, Ar4, Ar5 SON UN ANILLO DE 5-8 MIEMBROS; W ES OXI, TIO, SULFINO, SULFONILO, AMINOSULFONILO, ENTRE OTROS; X ES UN ANILLO AROMATICO DE 5-6 MIEMBROS Y UN POLIMERO DE POLI(LACTIDA-CO-GLICOLIDA) BIOCOMPATIBLE Y BIODEGRADABLE. SON COMPUESTOS PREFERIDOS ACIDO 7-[(4-BUTILBENCIL)-METASULFONILAMINO]-HEPTANOICO; ACIDO 7-{[2-(3,5-DICLOROFENOXI)-ETIL]-METASULFONILAMINO}-HEPTANOICO; ENTRE OTROS. LA COMPOSICION POTENCIA LA REPARACION, CURACION DE HUESOS, RESTAURA O AUMENTA LA MASA OSEA
PE2002001133A 2001-11-30 2002-11-26 Composiciones farmaceuticas y procedimientos para administrar agonistas selectivos del receptor ep2 PE20030660A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33515601P 2001-11-30 2001-11-30

Publications (1)

Publication Number Publication Date
PE20030660A1 true PE20030660A1 (es) 2003-08-04

Family

ID=23310510

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002001133A PE20030660A1 (es) 2001-11-30 2002-11-26 Composiciones farmaceuticas y procedimientos para administrar agonistas selectivos del receptor ep2

Country Status (24)

Country Link
US (1) US20030166631A1 (es)
EP (1) EP1448182A1 (es)
JP (1) JP2005513030A (es)
KR (1) KR20040063981A (es)
CN (1) CN1599605A (es)
AR (1) AR037593A1 (es)
AU (1) AU2002348948A1 (es)
BR (1) BR0214614A (es)
CA (1) CA2468494A1 (es)
GT (1) GT200200235A (es)
HN (1) HN2002000336A (es)
IL (1) IL161834A0 (es)
MX (1) MXPA04003689A (es)
NO (1) NO20042272L (es)
NZ (1) NZ532209A (es)
PA (1) PA8559601A1 (es)
PE (1) PE20030660A1 (es)
PL (1) PL370914A1 (es)
RU (1) RU2004116318A (es)
SV (1) SV2004001417A (es)
TW (1) TW200300342A (es)
UY (1) UY27556A1 (es)
WO (1) WO2003045371A1 (es)
ZA (1) ZA200402795B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA67754C2 (uk) * 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)
JP4666257B2 (ja) * 2003-07-25 2011-04-06 小野薬品工業株式会社 軟骨関連疾患治療剤
WO2005080367A1 (en) * 2004-02-12 2005-09-01 Pharmagene Laboratories Limited Ep2 receptor agonists
KR20070029247A (ko) * 2004-07-08 2007-03-13 노보 노르디스크 에이/에스 폴리펩티드 연장 태그
US8080567B2 (en) 2005-08-09 2011-12-20 Asterand Uk Limited EP2 receptor agonists
US7915316B2 (en) * 2005-08-22 2011-03-29 Allergan, Inc Sulfonamides
CA2644851A1 (en) * 2006-03-07 2007-09-13 Osteoscreen Ip, Llc Hmg co-a reductase inhibitor enhancement of bone and cartilage
AP2009004754A0 (en) * 2006-07-28 2009-02-28 Pfizer Prod Inc EP2 agonists
WO2008058766A1 (en) 2006-11-16 2008-05-22 Bayer Schering Pharma Aktiengesellschaft Ep2 and ep4 agonists as agents for the treatment of influenza a viral infection
AU2008289485B2 (en) * 2007-08-21 2014-08-14 Senomyx, Inc. Human T2R bitterness receptors and uses thereof
EP2149552A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma AG 5,6 substituierte Benzamid-Derivate als Modulatoren des EP2-Rezeptors
EP2149551A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma AG N-(Indol-3-ylalkyl)-(hetero)arylamidderivate als Modulatoren des EP2-Rezeptors
EP2149554A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma Aktiengesellschaft Indolylamide als Modulatoren des EP2-Rezeptors
WO2010116270A1 (en) 2009-04-10 2010-10-14 Pfizer Inc. Ep2/4 agonists
FR3034678A1 (fr) * 2015-04-07 2016-10-14 Geocorail Dispositif, procede et compose pour la reconstruction osseuse d'un vertebre.
WO2017139561A1 (en) 2016-02-12 2017-08-17 Bluebird Bio, Inc. Vcn enhancer compositions and methods of using the same
IL261002B2 (en) * 2016-02-12 2024-07-01 Bluebird Bio Inc Preparations of a VCN amplifier and methods of using them
EP3946345A4 (en) * 2019-04-04 2023-01-04 Intra-Cellular Therapies, Inc. METHODS OF TREATMENT OF NEUROPATHIC PAIN
EP4103192A4 (en) 2020-02-12 2024-02-21 Cytoagents, Inc. COMPOSITIONS AND METHODS FOR TREATING CORONAVIRUS INFECTIONS

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4789663A (en) * 1984-07-06 1988-12-06 Collagen Corporation Methods of bone repair using collagen
UA59384C2 (uk) * 1996-12-20 2003-09-15 Пфайзер, Інк. Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
DK0951282T3 (da) * 1996-12-20 2008-07-14 Pfizer Forebyggelse og behandling af skeletlidelse med EP2-receptorsubtype-selektive prostaglandin E2-agonister
US6071982A (en) * 1997-04-18 2000-06-06 Cambridge Scientific, Inc. Bioerodible polymeric semi-interpenetrating network alloys for surgical plates and bone cements, and method for making same
UA67754C2 (uk) * 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)
US20010056060A1 (en) * 2000-02-07 2001-12-27 Cameron Kimberly O. Treatment of osteoporsis with EP2/EP4 receptor selective agonists

Also Published As

Publication number Publication date
ZA200402795B (en) 2005-04-13
CA2468494A1 (en) 2003-06-05
TW200300342A (en) 2003-06-01
EP1448182A1 (en) 2004-08-25
GT200200235A (es) 2003-06-25
CN1599605A (zh) 2005-03-23
SV2004001417A (es) 2004-02-24
AU2002348948A1 (en) 2003-06-10
US20030166631A1 (en) 2003-09-04
NO20042272L (no) 2004-07-28
PA8559601A1 (es) 2003-07-28
NZ532209A (en) 2007-05-31
HN2002000336A (es) 2003-02-10
WO2003045371A1 (en) 2003-06-05
RU2004116318A (ru) 2005-03-27
KR20040063981A (ko) 2004-07-15
PL370914A1 (en) 2005-06-13
UY27556A1 (es) 2003-06-30
JP2005513030A (ja) 2005-05-12
AR037593A1 (es) 2004-11-17
IL161834A0 (en) 2005-11-20
MXPA04003689A (es) 2004-07-23
BR0214614A (pt) 2004-09-14

Similar Documents

Publication Publication Date Title
PE20030660A1 (es) Composiciones farmaceuticas y procedimientos para administrar agonistas selectivos del receptor ep2
HUP0402133A3 (en) Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar), process for their preparation and pharmaceutical compositions containing them
FR16C1001I1 (fr) "Dérivé de 2-oxo-1-pyrrolidine et ses applications pharmaceutique"
UA92603C2 (ru) Фармацевтическая композиция для лечения тромбоза
TR200200518T2 (tr) Felç, Diyabet ve/veya Konjesif Kalp Yetmezliğinin Önlenmesinde Kullanılan Farmolojik Formulasyonlar
NZ515705A (en) Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor (PPAR) alpha
MXPA05002871A (es) Derivados de benzodiazaepina y composiciones farmaceuticas que los contienen.
DE60207831D1 (de) Thiol-modifizierte hyaluronan-derivate
PT1061900E (pt) Composicoes e metodos para libertacao de uma droga
EP0871435A4 (en) THREE DIFFERENT FORMULATION OF POLYMERS WITH DELAYED RELEASE
TNSN05189A1 (en) Medium-chain length fatty acids, glycerides and analogues as stimulators of erythropoiesis
DK1073467T3 (da) Formuleringer med co-oplösningsmiddel omfattende en forbindelse af vitamin D
NZ516718A (en) Novel hydantoin, thiohydantoin, pyrimidinedione and thioxopyrimidinone derivatives, preparation method and use as medicines
MXPA04011914A (es) Formulacion farmaceutica de liberacion modificada.
CY1106633T1 (el) Φαρμακευτικες συνθεσεις οι οποιες περιεχουν χαλκο, σαλικυλικο οξυ και βιταμινη c
NO20020084L (no) Vedvarende frigivelsessammensetninger, fremgangsmåter for fremstilling av disse, og anvendelse av disse
MXPA05013390A (es) Composicion para el cuidado de la piel que comprende un agente aclarador de la piel.
ATE198472T1 (de) Gluteminsäurerezeptor agonisten
EP1019047A4 (en) ANTITHROMBOTIC AGENTS
CA2310028A1 (en) High drug load immediate and modified release oral dosage formulations and processes for their manufacture
NZ515108A (en) Novel ribose-substituted aromatic amides, method for the production and use thereof as medicaments
EP1027051A4 (en) ANTITHROMBOTIC AGENTS
TNSN06151A1 (en) Nitrooxyderivatives of antihypertensive drugs
ATE236885T1 (de) Hydrazono-benzazulen-derivate, pharmazeutische zusammensetzungen und zwischenprodukte
DE60206940D1 (de) Pektin und ascorbinsäure enthaltende zusammensetzungen

Legal Events

Date Code Title Description
FA Abandonment or withdrawal